Rabu, 26 Juni 2024

"A New Era Is Beginning"

Shield

AN OXFORD CLUB PUBLICATION

Wealthy Retirement

View in browser

SPONSORED

**URGENT AI BIOTECH EVENT**

In the coming days, an AI biotech - currently trading for less than $10 - is expected to make a bombshell announcement. And I do mean BOMBSHELL.

These announcements have historically been known to generate FAR more explosive gains than FDA approval... and in a MUCH shorter time...

As much as 509% MORE gains in some cases.

Companies that have made similar announcements have seen their shares positively SOAR.

Ambrx Biopharma
 

And on June 27 at 2 p.m. ET, America's #1 stock catalyst expert wants to give you all the details. Including why this coming announcement could be bigger and more important than anything we've seen in a lifetime.

Claim a free spot to attend right here.

Editor's Note: A couple of months ago, Chief Income Strategist Marc Lichtenfeld was researching biotech stocks that are involved with artificial intelligence, and he'd found one he was quite intrigued by...

But then he found a different company that absolutely blew him away.

He quickly sent out an email to several members of our team, writing that the company "has potential to be an all-time great drug company."

Tomorrow at 2 p.m. ET, Marc will host an urgent live broadcast to share more details on how an upcoming announcement from this company could spark an "AI Biotech Revolution."

This could be your last chance to register for this free event...

Click here to claim your spot now!

- James Ogletree, Managing Editor

"A New Era Is Beginning"

Marc Lichtenfeld, Chief Income Strategist, The Oxford Club

Marc Lichtenfeld

Steve Jobs predicted, "The biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning."

And we're starting to see that happen.

As I told you on Saturday, some experts predict that by 2040, generative AI could result in $1 trillion in value for healthcare.

Nvidia CEO Jensen Huang said it will be "the next amazing revolution [and] one of the biggest ever."

Those are powerful words coming from someone like him.

But let me be clear... This isn't just biotech 2.0.

This revolution is so huge and so radical that scientists have come up with an entirely new word for it...

TechBio.

It's more than just a buzzword. It's a true paradigm shift.

Biotech typically starts with the biological elements - living organisms, biological molecules, genetic material, etc. - and then applies data analysis, engineering principles and technology to manipulate or harness those biological components for desired products or outcomes.

TechBio, on the other hand, often begins from an engineering, data science or technological standpoint. It leverages tools, devices, computational power and technologies first and then applies or integrates them with biological systems to study, measure or interface with those living systems.

TechBio signifies a uniquely sophisticated method of drug development.

And it can't be done without AI.

SPONSORED

Yours Free! Top FIVE Dividend Stocks Right Now

Marc Lichtenfeld - income expert and author of Get Rich with Dividends - is giving away his Ultimate Dividend Package... completely free of charge!

You'll discover...

  • An "A"-rated, ultra-safe dividend stock with a huge 8% yield
  • Three of Marc's favorite "Extreme Dividend" stocks, which could supercharge your income
  • And finally, Marc's No. 1 dividend stock for a LIFETIME of income.

Click here to get the names and ticker symbols now... before the download link expires.

**NO CREDIT CARD REQUIRED!**

Thanks to these innovations, we're starting to see how AI can accelerate the whole process of discovery and testing new compounds. It's taking a fraction of the time... in some cases making the process as much as 15 times faster.

A study by Carnegie Mellon suggests AI could ultimately cut costs by as much as 70%.

So AI is just the thing that will ignite a massive rally in these stocks. And soon.

But that's not all...

A Perfect Storm Is Brewing

The cherry on top?

Morgan Stanley analysts point out that a Fed rate cut will also fuel these stocks, writing, "In our view, there have been green shoots pointing to the beginnings of a rally in the biotech industry."

All year, I've been saying rate cuts wouldn't come as quickly as most people expected, and I've been proven right. But one is coming eventually.

And when that happens, look for this corner of the market to really take off.

Why?

Low rates provide a favorable financing environment and increase the valuations of biotech firms' pipelines, driving outperformance in the sector.

Add it all up, and there's NEVER been a better time to jump into this market.

Tomorrow at 2 p.m. ET, I'm hosting a special broadcast to discuss the unique way I plan on playing this situation for maximum potential gains.

It's free to attend. Go here to make sure your name is on my list!

Good investing,

Marc

P.S. We're also offering a free gift for people who register for the event and sign up to be a VIP.

Just click here to register and claim your gift.

Leave a Comment
The Oxford Club's Wealth, Wine and Wander Tour with Marc Lichtenfeld in Munich, Salzburg, Vienna and Venice from December 1-10, 2024

New IPO Signs MAJOR Deal with Apple Until 2040. Will It Be the Next Trillion Dollar Company?

The Sweet Spot to Invest in the Biotech Sector

3-Minute Stock Secret Message: Learn the Little-Used Technique That Delivered Gains up to 227% in a Single Month

How Shareholders - Like You - are Public Benefactors

SPONSORED

Amazon's $794M Bombshell: Nvidia's Secret Partner Revealed

Seattle Spheres on May 2018
 

Amazon has quietly poured $144 million into a secretive AI chip company, and committed to buying a staggering $650 million of their product. Why? Because this obscure startup holds the key to unleashing the full potential of Nvidia's revolutionary Blackwell chip. Discover the company at the heart of the AI arms race.

Tidak ada komentar:

Posting Komentar